Drug Profile
Alofanib - Russian Pharmaceutical Technologies
Alternative Names: RPT-835Latest Information Update: 01 Aug 2022
Price :
$50
*
At a glance
- Originator Russian Pharmaceutical Technologies
- Class Antineoplastics; Benzoic acids; Pyridines; Small molecules; Sulfonamides
- Mechanism of Action Type-2 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Gastric cancer
- No development reported Breast cancer; Ovarian cancer
Most Recent Events
- 01 Aug 2022 Phase-I trial in Gastric cancer (Late-stage disease, Second-line therapy or greater) is ongoing in Russia (IV)
- 28 Jun 2022 No recent reports of development identified for phase-I development in Gastric-cancer(Late-stage disease, Second-line therapy or greater) in Russia (IV)
- 03 Jun 2022 Pharmacokinetics, efficacy and adverse data from a phase Ib trial in Gastric cancer presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)